NOXXON announces the convening of an extraordinary general meeting of shareholders

BERLIN, April 14, 2022–(BUSINESS WIRE)–Regulatory news:

NOXXON Pharma AG (Euronext Growth Paris: ALNOX) (Paris:ALNOX)a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), today announced that an extraordinary general meeting of shareholders (the EGM) of the company is convened at 1:30 p.m. CEST on May 16, 2022, at the offices of Freshfields Bruckhaus Deringer LLP, Strawinskylaan 10, 1077 XZ in Amsterdam, The Netherlands.

This EGM is convened to request the approval of the partial modification of the articles of association and the delegation of authority to cancel up to the maximum number of shares held by the company in its own capital in relation to the share consolidation project.

Bryan Jennings, CFO of NOXXON, said: “We are pursuing equity consolidation to improve our equity liquidity, reduce share price volatility and position NOXXON to access all funding markets in the future. We continue to assess the various global stock exchanges as potential hosts for our stocks to attract the highest quality investors globally.”

The documentation for the EGM, i.e. the convocation, the agenda and the explanatory notes to points 2 and 3 of the agenda, the instructions and documents for participation and voting at EGM are available on the company’s website ( These documents are also available at the registered office of the company, Max-Dohrn-Strasse 8-10, 10589 Berlin, Germany, for shareholders and persons entitled to attend the meeting who, on simple request, will receive one. copy for free.

Under Dutch law and the company’s articles of association, the persons entitled to attend and vote at the EGM are shareholders of the company (which, for the purposes of this notice, includes holders of a right of usufruct of Dutch law) who (i) were registered as a shareholder in one of the administrative registers of intermediaries who are (indirectly) participants in Euroclear France on April 18, 2022 (the Record Date) after all debit entries and have been processed on the Record Date and (ii) have notified the company before 5:00 p.m. CEST on May 09, 2022, of their presence in writing or electronically (contact details available on the company’s website).


NOXXON’s oncology-focused pipeline acts on the tumor microenvironment (TME) and cancer immunity cycle by breaking down the tumor protective barrier and blocking tumor repair. By neutralizing chemokines in the TME, NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. NOXXON’s main program, NOX-A12, provided the final front-line data from a Keytruda® combination trial in patients with metastatic colorectal and pancreatic cancer published at the ESMO conference in September 2020 and in July 2021 the company announced its phase 2 study, OPTIMUS, to further assess safety and efficacy NOX-A12 in combination with Keytruda from Merck® and two different chemotherapy regimens as second-line therapy in patients with metastatic pancreatic cancer. NOXXON is also studying NOX-A12 in brain cancer in combination with radiation therapy, which has been granted orphan drug status in the US and EU for the treatment of certain brain cancers. GLORIA, a trial of NOX-A12 in combination with radiation therapy in newly diagnosed brain cancer patients who will not clinically benefit from standard chemotherapy, provided frontline data from all three climbing cohorts of dose showing consistent tumor reductions and objective tumor responses. Additionally, GLORIA was expanded to assess the benefit of NOX-A12 with other treatment combinations, radiotherapy + bevacizumab and radiotherapy + pembrolizumab. The Company’s second clinical-stage asset, NOX-E36, is a Phase 2 TME asset targeting the innate immune system. NOXXON plans to test NOX-E36 in patients with solid tumors. Further information can be found at:

Keytruda® is a registered trademark of Merck Sharp & Dohme Corp.

Visit NOXXON at LinkedIn and Twitter.

About the GLORIA study

GLORIA (NCT04121455) is NOXXON’s dose-escalating Phase 1/2 study of NOX-A12 in combination with radiation in first-line patients with partially resected or unresected glioblastoma (brain cancer) with a promoter Unmethylated MGMT (resistant to standard chemotherapy). GLORIA is further evaluating the safety and efficacy of NOX-A12 in three additional arms combining NOX-A12 with: A. radiation therapy in patients with complete tumor resection; B. radiotherapy and bevacizumab in patients with incomplete tumor resection; and C. radiation therapy and pembrolizumab in patients with incomplete tumor resection.

About the OPTIMUS study

OPTIMUS (NCT04901741) is NOXXON’s open-label, two-arm Phase 2 study of NOX-A12 plus pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab-paclitaxel in patients with stable microsatellite metastatic pancreatic cancer.


Translations of any press release into languages ​​other than English are for the convenience of non-English speaking audiences only. The company has attempted to provide an accurate translation of the original English text, but due to nuances of translating into another language, slight differences may exist. Certain statements in this communication contain formulations or terms that refer to future or future developments, as well as negations of these formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information contained in this communication regarding expected or future results of business segments, financial indicators, changes in financial condition or other financial or statistical data contains such forward-looking statements. The company cautions potential investors not to rely on these forward-looking statements as certain predictions of actual future events and developments. The company is neither responsible nor liable for updating this information, which only represents the current situation on the day of publication.

See the source version on


Aram Mangasarian, Ph.D.
Chief executive officer
Such. +49 (0) 30 726247 0
[email protected]

Investor and Media Relations:

LifeSci Advisors
Guillaume van Renterghem
Such. +41 (0) 76 735 01 31
[email protected]

Arthur Rusty
Such. +33 (0)1 44 71 00 15
[email protected]

About Margie Peters

Check Also

Actions that will come into action on November 11, 2022

Alkem Laboratories said the US health regulator issued three observations after inspecting its St Louis-based …